Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations

Ritonavir-boosted atazanavir is an option for second-line therapy in low- and middle-income countries (LMICs). We analyzed publicly available HIV-1 protease sequences from previously PI-naïve patients with virological failure (VF) following treatment with atazanavir. Overall, 1497 patient sequences...

Full description

Bibliographic Details
Main Authors: Soo-Yon Rhee, Michael Boehm, Olga Tarasova, Giulia Di Teodoro, Ana B. Abecasis, Anders Sönnerborg, Alexander J. Bailey, Dmitry Kireev, Maurizio Zazzi, the EuResist Network Study Group, Robert W. Shafer
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Pathogens
Subjects:
HIV-1
antiviral therapy
drug resistance
protease inhibitor
protease
mutation
Online Access:https://www.mdpi.com/2076-0817/11/5/546

Internet

https://www.mdpi.com/2076-0817/11/5/546

Similar Items